A new article in The Journal of Nuclear Medicine explores the potential for using ChatGPT, an artificial intelligence chatbot, in nuclear medicine and molecular imaging. The authors discuss the strengths and weaknesses of current AI bots and highlight the benefits of collaborating with AI allies to cope with increasing workloads.
Current radiotherapy contouring guidelines often miss lesions in the prostate bed, leading to unnecessary tissue irradiation. PSMA PET mapping reveals that nearly a third of patients experience disease progression within 10 years after radical prostatectomy.
A novel lensless radiomicroscope has been developed for nuclear medicine imaging, offering high-resolution images of cells with a field of view over 500 times larger than current technology. The instrument is made from off-the-shelf parts and costs less than $100, making it accessible to more labs.
A new radiotracer successfully detected 100% of primary tumors across multiple cancer types, outperforming the current standard. It also showed promise in detecting lymph node and distant metastases, offering a promising alternative for diagnosis and treatment.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have published a new procedure standard/practice guideline for somatostatin receptor (SSTR) PET imaging in patients with neuroendocrine tumors. The guideline focuses on improved sensitivity, lower radiation dose, and sh...
A novel nuclear medicine imaging protocol, dual-phase amyloid PET, can assess both amyloid deposition and neurodegeneration with a single tracer injection, cutting costs and radiation exposure. The protocol was shown to be comparable in distinguishing patients with neurodegenerative diseases from controls.
A new study published in The Journal of Nuclear Medicine found that e-cigarette users have greater lung inflammation than cigarette smokers and non-smokers. The study used PET imaging to compare lung inflammation between e-cigarette users and cigarette smokers, revealing a unique inflammatory response in the lungs.
A study found that nearly half of Medicare patients with non-small cell lung cancer do not receive the recommended FDG PET/CT imaging prior to radiation therapy, leading to decreased overall and cancer-specific survival rates. This lack of adherence is linked to greater mortality rates.
A novel imaging agent, 68Ga-FAPI, has been shown to reduce the number of false-positive PET/CT findings among cancer patients recently vaccinated for COVID-19. This can help prevent costly follow-up and false management decisions for cancer patients.
PSMA PET/MRI successfully determines prostate cancer likelihood of return within two years after prostatectomy, aiding treatment decisions. High uptake in primary lesion and metastasis are associated with rapid recurrence.
A new study found that approximately three percent of all bone scan patients have markers of cardiac amyloidosis, which can lead to heart failure and increased mortality. The research highlights the importance of early diagnosis and treatment, as well as potential automated detection methods using machine-learning algorithms.
A new molecular imaging radiotracer, <sup> 68 </sup> Ga-PentixaFor, demonstrates high image contrast in various cancers, including hematologic malignancies and small cell lung cancer. This agent targets the C-X-C motif chemokine receptor 4 (CXCR4), which is a predictor of poor prognosis in cancer patients.
A new study published in The Journal of Nuclear Medicine found that a PET/MRI machine learning model can reliably distinguish between patients with and without lymph node metastases. This breakthrough technology has the potential to eliminate sentinel lymph node biopsy, a common procedure for breast cancer treatment.
A new radiotracer, 18F-SMBT-1, detects overexpressed monoamine oxidase-B in cognitively unimpaired individuals with high beta amyloid levels, a key early sign of Alzheimer's disease. The agent shows increased binding to reactive astrocytes, suggesting its potential as a surrogate marker for detecting Alzheimer's disease.
Researchers successfully visualized systemic joint involvement in patients with autoimmune arthritis using ultra-low dose total body PET/CT scans. The scans showed high agreement with standard joint-by-joint rheumatological evaluations and a moderate to strong correlation with rheumatological outcome measures.
A novel PET radiotracer has been developed to assess tumor aggressiveness in neuroendocrine neoplasms, providing valuable information for personalized care. High uPAR expression was associated with a worse prognosis, making it a potential target for therapy.
The Journal of Nuclear Medicine Technology special issue highlights the potential of theranostics to tailor cancer treatment to individual patients. The innovation uses targeted radiopharmaceuticals for both diagnosis and treatment of tumors.
A new study shows that PSMA PET/CT imaging can change treatment plans for nearly 50% of patients with prostate cancer recurrence after radical prostatectomy. The imaging technique detected disease in 46.9% of patients, leading to major changes in treatment plans, including recommendations for additional treatments.
The Journal of Nuclear Medicine publishes a first-hand account of daily nuclear medicine practice in Kyiv, Ukraine, where physicians face constant bombing and shelling. Despite the challenges, Dr. Kmetyuk expresses gratitude for international support and hope for the future of Ukrainian medical professionals.
The Journal of Nuclear Medicine has achieved an impact factor of 11.082, a 10% increase over last year's score of 10.057. This marks the highest impact factor in the journal's history, reflecting the growing importance of nuclear medicine as a whole.
A new SPECT imaging system performs scans 10-100 times faster than current systems, offering better image quality and increased patient throughput. The self-collimation concept improves traditional SPECT imaging by reducing scan time and radiation exposure.
A targeted radionuclide alpha therapy called 225Ac-DOTATATE has shown promising survival rates and an acceptable toxicity profile in patients with advanced-stage gastroenteropancreatic neuroendocrine tumors. Minimal toxicities were noted after treatment.
Current guidelines for salvage radiation treatments in patients with local recurrence of prostate cancer should be updated to consider information from PSMA PET imaging. PSMA PET is effective in identifying recurrences partially or fully outside the clinical target volume, suggesting its value for therapy planning.
A new PET imaging agent, <sup>68</sup> Ga-FAPI-46, has been shown to predict the severity of cardiac remodeling after a heart attack by identifying active fibrosis. This biomarker has potential to aid in diagnosis and treatment selection for patients with heart failure.
A newly developed small-molecular radiopharmaceutical pair has successfully visualized and treated melanoma in a preclinical study. The theranostic approach targets metabotropic glutamate receptor 1 (GRM1) found in many human solid tumors.
Cathy Sue Cutler, PhD, was elected vice president-elect of SNMMI, focusing on securing funding for nuclear medicine services. She aims to generate training opportunities for SNMMI members on theranostics and educate the public on the value of nuclear medicine.
Munir Ghesani, MD, has been elected as president of SNMMI for his commitment to improving patient access to nuclear medicine scans. He plans to address issues such as reimbursement and regulatory approvals to grow the field of nuclear medicine.
Dr. Simon R. Cherry received the 2022 Benedict Cassen Prize for his groundbreaking contributions to nuclear medicine instrumentation and molecular imaging. He was recognized for his pioneering advancements in small-animal PET, PET/MRI hybrid imaging, and total-body PET.
Schwaiger received the SNMMI Georg Charles de Hevesy Nuclear Pioneer Award for his significant work in multimodal imaging and development of novel quantitative methods. His research interests included oncologic PET, thyroid endocrine, and neuroendocrine diseases.
Dmitry Beyder has been elected as the 2022-23 president-elect for the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS). As president-elect, Beyder will focus on guiding technologists out of the COVID-19 pandemic and strengthening the nuclear medicine technologist workforce and professional pipeline.
The SNMMI has launched the Mars Shot Fund to support innovative nuclear medicine and molecular imaging research. The fund aims to secure $100 million in funding and is currently at $600,000, following generous donations from individuals and organizations.
Helen Nadel, MD, FRCPC, has been named president-elect of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). She plans to address issues such as global communication, government and industry relationships, and diversity initiatives. With over 30 years of SNMMI membership, Nadel brings extensive experience to her role.
Krystle W. Glasgow has been elected as the 2022-23 president of the Society of Nuclear Medicine and Molecular Imaging Technologist Section, aiming to increase membership and enhance communication and educational offerings for nuclear medicine technologists.
Andrei Iagaru has received the inaugural Sam Gambhir Trailblazer Award from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) for his outstanding contributions to transformative research and exceptional mentorship. He is recognized for his work in PET/MRI, PET/CT, and targeted radionuclide therapy.
The Society of Nuclear Medicine and Molecular Imaging has recognized 15 new SNMMI Fellows, including past president Richard Wahl, MD, for their excellence in volunteer service, scientific discovery, and clinical practice. The SNMMI Fellowship is one of the most prestigious formal recognitions available to long-time members.
A new PET imaging agent, 18F-AlF-FAPI-74, has been found to effectively monitor and predict treatment response of an up-and-coming cancer therapy. This non-invasive imaging approach can help inform clinical decision-making early in the course of treatment.
Researchers developed an artificial intelligence method to generate high-quality 'PET/CT' images, reducing radiation exposure and allowing for more frequent imaging. This innovation has the potential to provide more accurate assessment of disease progression and treatment efficacy, ultimately improving patient care.
A new ultra-low dose PET technique eliminates the need for a CT scan, significantly reducing patient radiation exposure. The technique uses background radiation to reconstruct attenuation maps and quantitative PET images, with an average organ quantitative error of 4.8-10 percent.
A novel somatostatin-receptor targeting peptide has shown excellent imaging in patients with meningiomas, identifying previously undetected lesions. The new agent offers significant logistical advantages, including a longer half-life and large-scale production capabilities.
A novel targeted radionuclide alpha therapy, AC-NM600, has been shown to achieve significantly better outcomes than its corresponding beta therapy in treating metastatic castration-resistant prostate cancer. The study demonstrated slowed tumor growth and improved overall survival.
A study using PET/CT revealed that residual COVID-19 symptoms can be attributed to ongoing lung inflammation. Treatment with steroids and antifibrotic drugs significantly decreased inflammatory activity.
A study using PET imaging found that severe obstructive sleep apnea is associated with abnormal heart blood flow reserve, increasing the risk of heart disease. The findings suggest that cardiac PET imaging can identify high-risk OSA patients.
The JNM Molecular Imaging of Neurodegeneration Supplement provides an overview of molecular imaging techniques in neurodegenerative disorders. The supplement aims to improve early and differential diagnosis, as well as stratify and monitor therapy in these disorders.
The SNMMI Annual Meeting will focus on precision medicine, developing new diagnostic methods and treatments for cancers, brain diseases, and cardiac conditions. The event will feature breaking news and research in nuclear medicine and molecular imaging.
A study found that higher levels of active brown adipose tissue are associated with early metabolic dysfunction and pre-cooling glucose, insulin, thyroid stimulating hormone, and triglyceride levels. Activated brown fat was recruited to counteract 'pre-prediabetic' states, potentially serving as a first-line protective mechanism.
The joint guide provides a framework for establishing theranostic centers globally, focusing on safety protocols and operational procedures. It highlights best practices for radiation protection, storage, administration, and other topics to improve patient care.
A new deep learning method, PDD-Net, uses 3D deep convolutional neural networks to extract deep metabolic imaging indices from PET scans for differential diagnosis of parkinsonian diseases. The method achieved high sensitivity and specificity rates for Parkinson's disease and other parkinsonian syndromes.
A novel nuclear medicine combination therapy combining <sup> 177 </sup> Lu-PSMA-617 with idronoxil (NOX66) has been shown to be safe and effective in reducing PSA levels by over 50% in men with metastatic prostate cancer. The median overall survival was 19.7 months, suggesting potential for improved patient outcomes.
A comprehensive literature review of molecular imaging findings indicates that COVID-19 neurological complications such as fatigue and cognitive impairment are often reversible. The study identifies important implications for other neurological conditions like Parkinson's disease and Alzheimer's disease.
A novel radioligand therapy has been shown to increase progression-free survival (PFS) and overall survival (OS) of metastatic castration-resistant prostate cancer (mCRPC) patients. Ninety-one percent of patients experienced a greater than 50% reduction in PSA values after treatment, with a median PFS of 22 months.